GENENTECH, INC for GENENTECH INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
Trade (domestic/foreign) TRD
Trade with India.; Proposed changes in global patent protections. Compulsory License Issues in India
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Asst. Director |
Copyright/Patent/Trademark CPT
Cyber security, Transpacific Partnership
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN MORRIS | vice President of Government Affairs |
Taxation/Internal Revenue Code TAX
Monitoring of the FY 14 appropriations bills and issues related to comprehensive tax reform.; Research and Development Tax credit,; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| DARIN GARDNER | Sr. Director Government Affairs |
| ELI KOGAN | Asst. Director |
Health Issues HCR
Issues relating to the treatment of biologics in international health programs; proposed cuts to Part B reimbursement. 340b reimbursement policy; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Issues concerning trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R. 1416, Cancer Patient Protection Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; Pandemic preparedness, Tamiflu, Medicare coverage of Cancer Drugs, Appropriations; implementation of section 340B of the Public Health Service Act (42 U.S.C. 256b); Issues relating to the treatment of biologics in international health programs
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs - Roche Diagnostics |
| KATHERINE RAAB | Director of Government Affairs |
Medicare/Medicaid MMM
Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues.; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and biologics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis; Concerns regarding Medicare payment policies for Part B drugs. HCR: Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; Medicare coverage and payment of Part B drugs and biologicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening, care and treatment, and access t breast cancer treatment; Following issues related to the budget and appropriations process FY 13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Asst. Director |
| ELI KOGAN | Asst. Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.